Skip to main content

Table 4 Summary of treatment-emergent AEs

From: A phase 3 trial assessing the efficacy and safety of grass allergy immunotherapy tablet in subjects with grass pollen-induced allergic rhinitis with or without conjunctivitis, with or without asthma

 

Placebo (n = 166)

Grass AIT (n = 163)

 

N (%)*

Events

N (%)*

Events

All

101 (61)

258

121 (74)

454

Causality

    

  Probably related

11 (7)

23

73 (45)

184

  Possibly related

13 (8)

29

20 (12)

29

  Unlikely related

93 (56)

206

95 (58)

241

Severity

    

  Mild

70 (42)

146

100 (61)

268

  Moderate

57 (34)

94

75 (46)

156

  Severe

14 (8)

18

20 (12)

30

  1. *Represents all subjects experiencing AE of each causality/severity; each subject could experience AEs in multiple categories of causality/severity. AE Adverse event, AIT Allergy immunotherapy tablet.